1）Packer M, et al. Comparative effects
of low and high doses of theangiotensin-converting enzyme inhibitor, lisinopril,
on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
2）Waagstein F, et al. Effect of chronic beta-adrenergic
receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
3）CIBIS II investigators and committees. The cardiac
insufficiency bisoprolol study II （CIBIS II); a randomised trial. Lancet
1999;353:9-13.
4）MERIT-HF study group. Effect of metoprolol CR/XL in
chronic heart failure: metoprolol CR/XL randomised intervention trial
in congestive heart failure（MERIT-HF). Lancet 1999;353:2001-7.
5）Packer M, et al. The effect of carvedilol on morbidity
and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
6）Heart Failure Society of America. HFSA guidelines for
management of patients with heart failure caused by left ventricular
systolic dysfunction ? pharmacological approaches. J Card Fail 1999;5:357-82.
7）Pitt B, et al. Randomised trial of losartan versus
captipril in patients over 65 with heart failure. Lancet 1997;349:747-52.
8）Pitt B, et al. Effect of losartan compared with captopril
on mortality in patients with symptomatic heart failure: randamized
trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355;1582-7.
9）McKelvie RS, et al. Comparison of candesartan, enalapril,
and their combination in congestive heart failure: Randamized Evaluation
of Strategies for Left Ventricular Dysfunction （RESOLVD) pilot study.
Circulation 1999;100:1056-64.
10）Pitt B, et al. The effect of spironolactone on morbidity
and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
11）Amiodarone Trials Meta-Analysis Investigators. Effect
of prophylactic amiodarone on mortality after acute myocardial infarction
and in congestive heart failure: meta-analysis of individual data from
6500 patients in randomized trials. Lancet 1997;350:1417-24.
12）Kaye DM, et al. Antiadrenergic effect of chronic
amiodarone therapy in human heart disease. J Am Coll Cardiol 1999;33:1553-9.
13）Reis SE, et al. Estrogen is associated with improved
survival in aging women with congestive heart failure: analysis of the
vesnarinone studies. J Am Coll Cardiol 2000;36:529-33.
14）Agnoletti L, et al Serum from patients with severe
heart failure downregulates
eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation
1999;100:1983-91.
15）Torre Amione G, et al. Decreased expression of tumor
necrosis factor-alpha in failing human myocardium after mechanical circulatory
support: a potential mechanism for cardiac recovery. Circulation 1999;100:1189-93
16）Deswal A, et al. Safety and efficacy of a soluble
p75 tumor necrosis factor receptor （Enbrel, Etanercept） in patients
with advanced heart failure. Circulation 1999;99:3224-6.
17）Ide T, et al Direct evidence for increased hydroxy
radicals originating from superoxide in the failing myocardium. Circ
Res 2000;86:152-7
18）Yamamoto K, et al. Effect of the endogenous natriuretic
peptide system on ventricular and coronary function in failing heart.
Am J Physiol. 1997;273:H2406-14.
19）Tamura N, et al. Cardiac fibrosis in mice lacking
brain natriuretic peptide. Proc Natl Acad Sci USA 2000;97:4239-44
20）Colucci WS, et al. Intravenous nesiritide, a natriuretic
peptide, in the treatment of decompensated congestive heart failure.
N Engl J Med 2000;343:246-53